Vicore Pharma Holding
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
VICO | ST
Overview
Corporate Details
- ISIN(s):
- SE0007577895 (+1 more)
- LEI:
- 549300KTNBPTZLF01130
- Country:
- Sweden
- Address:
- Postbox 14, 414 51 Göteborg
- Website:
- https://vicorepharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of disease-modifying therapies by targeting the angiotensin II type 2 (AT2) receptor. The company's strategy focuses on activating this receptor to stop and reverse disease pathology, primarily in severe respiratory diseases such as idiopathic pulmonary fibrosis (IPF). Its lead drug candidate is buloxibutid (C21), a first-in-class, orally available small molecule AT2 receptor agonist (ATRAG) in clinical development. In addition to its drug pipeline, Vicore is developing Almee™, a cognitive behavioral therapy-based digital therapeutic designed to address the psychological impact of living with pulmonary fibrosis. Almee™ has received Breakthrough Device Designation from the U.S. FDA. The company utilizes its expertise in ATRAG chemistry and biology to expand its pipeline with new therapies for additional indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-28 09:00 |
Declaration of Voting Results & Voting Rights Announcements
Increase in number of shares and votes in Vicore Pharma
|
English | 107.0 KB | ||
| 2025-11-28 09:00 |
Declaration of Voting Results & Voting Rights Announcements
Ökning av antalet aktier och röster i Vicore Pharma
|
Swedish | 107.5 KB | ||
| 2025-11-27 10:04 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 10.7 KB | ||
| 2025-11-14 11:50 |
Major Shareholding Notification
|
Swedish | 10.4 KB | ||
| 2025-11-13 01:50 |
ISS
Vicore Pharma har framgångsrikt genomfört en riktad nyemission om cirka 48 milj…
|
Swedish | 127.3 KB | ||
| 2025-11-13 01:50 |
ISS
Vicore Pharma announces successful execution of a directed share issue of appro…
|
English | 125.9 KB | ||
| 2025-11-12 17:31 |
ISS
Vicore Pharma avser att genomföra en riktad nyemission av aktier
|
Swedish | 122.4 KB | ||
| 2025-11-12 17:31 |
ISS
Vicore Pharma intends to carry out a directed share issue
|
English | 120.9 KB | ||
| 2025-11-05 08:00 |
Quarterly Report
|
Swedish | 2.2 MB | ||
| 2025-11-05 08:00 |
Quarterly Report
|
English | 2.2 MB | ||
| 2025-11-03 09:00 |
Board/Management Information
Vicore announces the Nomination Committee for the 2026 Annual General Meeting
|
English | 104.6 KB | ||
| 2025-11-03 09:00 |
Board/Management Information
Vicore offentliggör valberedningen inför årsstämman 2026
|
Swedish | 108.2 KB | ||
| 2025-08-22 08:00 |
Interim Report
|
Swedish | 2.2 MB | ||
| 2025-08-22 08:00 |
Interim Report
|
English | 2.2 MB | ||
| 2025-06-30 09:00 |
Declaration of Voting Results & Voting Rights Announcements
Increase in number of shares and votes in Vicore Pharma
|
English | 102.5 KB |
Automate Your Workflow. Get a real-time feed of all Vicore Pharma Holding filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Vicore Pharma Holding
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Vicore Pharma Holding via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-13 | Ahmed Mousa | Other | Buy | 11,034 | 90,920.16 SEK |
| 2025-05-13 | Ahmed Mousa | Other | Buy | 757 | 6,230.11 SEK |
| 2024-10-24 | Johannes Schikan | Other | Other | 355 | 2,485.00 SEK |
| 2024-09-23 | Ann Barbier | Other | Buy | 42,500 | 298,775.00 SEK |
| 2024-09-11 | Ahmed Mousa | Other | Buy | 32,000 | 248,169.60 SEK |
| 2024-09-10 | Ahmed Mousa | Other | Buy | 95,000 | 752,248.00 SEK |
| 2022-06-08 | Jacob Uno Stanley Gunterberg | Other | Buy | 6,400 | 220,800.00 SEK |
| 2022-06-03 | Johannes Schikan | Other | Buy | 4,000 | 119,880.00 SEK |
| 2022-06-03 | Sara Malcus | Other | Buy | 2,902 | 87,495.30 SEK |
| 2022-06-01 | Maarten Kraan | Other | Buy | 4,025 | 121,152.50 SEK |
Peer Companies
